Deutsche Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Thursday. The firm currently has a GBX 5,700 ($77.30) target price on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on AZN. JPMorgan Chase & Co. set a GBX 5,500 ($74.59) target price on shares of AstraZeneca and gave the stock a buy rating in a research report on Thursday, January 4th. Sanford C. Bernstein set a GBX 5,780 ($78.38) target price on shares of AstraZeneca and gave the stock a buy rating in a research report on Monday, September 25th. Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Tuesday, October 31st. HSBC upped their target price on shares of AstraZeneca from GBX 4,340 ($58.86) to GBX 4,380 ($59.40) and gave the stock a reduce rating in a research report on Thursday, November 16th. Finally, UBS Group set a GBX 4,550 ($61.70) target price on shares of AstraZeneca and gave the stock a neutral rating in a research report on Monday, October 9th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,200.82 ($70.53).

AstraZeneca (LON AZN) opened at GBX 5,132 ($69.60) on Thursday. AstraZeneca has a 1 year low of GBX 4,136.50 ($56.10) and a 1 year high of GBX 5,520 ($74.86). The company has a market cap of $64,070.00 and a PE ratio of 2,515.69.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/astrazeneca-azn-rating-reiterated-by-deutsche-bank/1806855.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.